Enzene Biosciences Ltd.

home / authors / enzene-biosciences-ltd-

Articles

Quality, Risk, and Regulatory Drivers Behind Fully Connected Continuous Manufacturing

July 30th 2025

Biomanufacturing has relied on largely unchanged processes for decades, but today’s complex molecules require a smarter approach. Sundar Ramanan, Chief Quality Officer at Enzene, explains how fully-connected continuous manufacturing™ (FCCM™) enables this shift by integrating real-time monitoring, automation, and contamination control.

Fully-Connected Continuous Manufacturing™ as the Key to Cost Efficiency and Scalability in Biotech

Russell Miller;Enzene Biosciences Ltd.

April 22nd 2025

Innovative Fully-Connected Continuous Manufacturing™ technology and advanced facilities are revolutionizing biomanufacturing and driving cost efficiency, especially in monoclonal antibody production.

Enzene Expands Into the US and Will Provide State-of-the-Art Fully Connected Continuous Manufacturing Services to Pharma and Biotech Companies

Enzene Biosciences Ltd.

July 29th 2024

Dr Himanshu Gadgil, CEO, Enzene Biosciences Ltd., describes the rationale for expanding its services, including its patented EnzeneX™ continuous manufacturing technology platform, to emerging innovative, US-based biotech firms looking to benefit from the in-depth expertise in continuous manufacturing.